RCUS Q3 2024 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+50.0% YoY

Gross Profit

$48M100.0% margin

Operating Income

-$105M-218.8% margin

Net Income

-$92M-191.7% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

+23.1%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$25M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$687M

Stockholders' Equity

$565M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$32M	+50.0%
Gross Profit	$48M	$32M	+50.0%
Operating Income	-$105M	-$80M	-31.3%
Net Income	-$92M	-$71M	-29.6%

Revenue Segments

License and Development Services Revenue

$41M85%

Other Collaboration Revenue

$7M15%